2. Search Result
Search Result
Results for "

vasodilating

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

4

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101656
    Medroxalol

    RMI81968

    		 Adrenergic Receptor Cardiovascular Disease
    Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects .
    Medroxalol
  • HY-B1469
    Isosorbide

    D-Isosorbide; Dianhydro-D-glucitol

    		 Others Cardiovascular Disease Metabolic Disease
    Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic .
    Isosorbide
  • HY-113547
    Nanterinone

    UK 61260

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Nanterinone (UK 61260) is a positive inotropic and arterial vasodilating agent. Nanterinone is a phosphodiesterase inhibitor .
    Nanterinone
  • HY-P3092
    Phyllomedusin

    		Neurokinin Receptor Neurological Disease
    Phyllomedusin, an tachykinin decapeptide, is a NK1 receptor agonist. Phyllomedusin has vasodilating activity and provokes the contraction of the pylorus .
    Phyllomedusin
  • HY-14252A
    Milrinone lactate

    Win 47203 lactate

    		 Others Cardiovascular Disease
    Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock .
    Milrinone lactate
  • HY-114846
    Ro 22-9194

    		Prostaglandin Receptor Cardiovascular Disease
    Ro 22-9194 inhibits aggregation and thromboxane Az (TXA2) synthetase activity in rabbit and human platelets. Ro 22-9194 has a potent inhibitory action against various types of model arrhythmias. Ro 22-9194 has non-cholinergic cardiac depressant properties with its vasodilating action .
    Ro 22-9194
  • HY-B1639
    Enoximone

    		Phosphodiesterase (PDE) Cardiovascular Disease Inflammation/Immunology
    Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .
    Enoximone
  • HY-B1069
    Molsidomine

    SIN-10; Morsydomine

    		 Drug Metabolite Cardiovascular Disease
    Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.
    Molsidomine
  • HY-N0165
    Methyl-Hesperidin

    		Others Inflammation/Immunology
    Methyl-Hesperidin is a vasodilating agent .
    Methyl-Hesperidin
  • HY-B1435
    Moxisylyte hydrochloride

    Thymoxamine hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Moxisylyte (hydrochloride) is (alpha 1-blocker) antagonist, it can vasodilates cerebral vessels without reducing blood pressure.
    Moxisylyte hydrochloride
  • HY-100239
    ICI 153110

    		Phosphodiesterase (PDE) Cardiovascular Disease
    ICI 153110 is an orally active phosphodiesterase inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure.
    ICI 153110
  • HY-129088
    HUP30

    		Potassium Channel Calcium Channel Cardiovascular Disease
    HUP30 is a vasodilating agent. HUP30 stimulates soluble guanylyl cyclase, activate K + channels, and blocks extracellular Ca 2+ influx .
    HUP30
  • HY-100957
    Dilazep dihydrochloride

    Dilazep dihydrochloride is an inhibitor of adenosine uptake. Dilazep dihydrochloride has cerebral and coronary vasodilating action through enhancement of effect of adenosine. Dilazep dihydrochloride also inhibits the ischemic damage, platelet aggregation, and membrane transport of nucleosides .
    Dilazep dihydrochloride
  • HY-122537A
    Arotinolol

    		Adrenergic Receptor 5-HT Receptor Cardiovascular Disease
    Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
    Arotinolol
  • HY-115381
    Lipoxin A5

    		Endogenous Metabolite Cardiovascular Disease
    Lipoxin A5 is an eicosapentaenoic acid derived from pig white blood cells. Lipoxin A5 slowly contracted the guinea pig lung parenchymal strips with a contractile force similar to that of LXA4 and LXB4.2, but LXA5 did not have the vasodilating effect on the aortic smooth muscle shown by LXA4 and LXB4.2 .
    Lipoxin A5
  • HY-P1556
    Vasonatrin Peptide (VNP)

    		PKG Cardiovascular Disease
    Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
    Vasonatrin Peptide (VNP)
  • HY-P1556A
    Vasonatrin Peptide (VNP) (TFA)

    		PKG Metabolic Disease
    Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
    Vasonatrin Peptide (VNP) (TFA)
  • HY-W111226
    Fmoc-His(3-Me)-OH

    		Amyloid-β Amino Acid Derivatives Cardiovascular Disease
    Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC50s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca 2+]i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel .
    Fmoc-His(3-Me)-OH

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: